Depression News and Research

Latest Depression News and Research

Alkermes' ALKS 5461 drug gets FDA Fast Track status for major depressive disorder

Alkermes plc today announced that the U.S. Food and Drug Administration has granted Fast Track status for ALKS 5461 for the adjunctive treatment of major depressive disorder in patients with an inadequate response to standard therapies.

10 Oct 2013

Transcendental Meditation technique has large effect on reducing trait anxiety, shows analysis

A new meta-analysis published today in the Journal of Alternative and Complementary Medicine (2013;19(10):1-12)1 found the Transcendental Meditation- technique (TM) has a large effect on reducing trait anxiety for people with high anxiety.

10 Oct 2013

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. announced today the continuation of the development program of Lu AE58054 for the treatment of Alzheimer's disease, initiating the first out of four phase III clinical trials with the compound.

10 Oct 2013

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

Scientists at The Scripps Research Institute (TSRI) have identified a set of compounds that may be used to treat multiple sclerosis (MS) in a new way. Unlike existing MS therapies that suppress the immune system, the compounds boost a population of progenitor cells that can in turn repair MS-damaged nerve fibers.

10 Oct 2013

Risk of dying from invasive breast cancer lower among multivitamin/mineral users

Findings from a study involving thousands of postmenopausal women suggest that women who develop invasive breast cancer may benefit from taking supplements containing both multivitamins and minerals.

9 Oct 2013

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

Alkermes plc today announced that it has successfully completed its End-of-Phase 2 interactions with the U.S. Food and Drug Administration (FDA), and the company plans to advance ALKS 5461 into phase 3 development in early 2014.

9 Oct 2013

BUSM researchers develop screening tool to detect intimate partner violence in females

Boston University School of Medicine (BUSM) researchers have identified a promising screening tool to detect intimate partner violence (IPV) in females in the VA Boston Healthcare System.

9 Oct 2013

UCLA investigates high rates of schizophrenia in people with 22q11.2 deletion syndrome

UCLA has joined an international consortium to investigate the high rates of schizophrenia and other neuropsychiatric disorders in those who are affected with Chromosome 22q11.2 deletion syndrome, a disorder caused by the deletion of a small piece of chromosome number 22.

9 Oct 2013

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Alkermes plc (NASDAQ: ALKS) today announced completion of patient enrollment in the pivotal, multinational phase 3 study evaluating aripiprazole lauroxil in patients with schizophrenia.

9 Oct 2013

Bipolar disorder ‘distinct’ from borderline personality disorder

Researchers say that there are clear clinical differences between depressed patients with bipolar II disorder and those with borderline personality disorder, which supports the two being treated as distinct conditions.

8 Oct 2013

Short sleep duration linked to suicidal ideation

Short sleep duration is associated with an increased risk for suicidal ideation, a cross-sectional study of Korean adults shows.

8 Oct 2013

Depression impairs sleep in breast cancer, but being married helps

Women with metastatic breast cancer are more likely to experience sleep disturbances if they are depressed or single, researchers report.

8 Oct 2013

Retirement a sticking point for antihypertensive adherence

Patients’ adherence to their antihypertensive medication may decline when they retire from work, a study shows.

8 Oct 2013

Brain & Behavior Research Foundation to hold research symposium on mental health

The Brain & Behavior Research Foundation, an organization dedicated to improving the lives of those with mental illness through the transformative power of neuroscience and psychiatric research, will hold its 25th Annual Mental Health Research Symposium on Friday, October 25th from 9:00 am to 4:30 p.m. at the Kaufman Music Center, located at 129 W. 67th St. in New York City.

8 Oct 2013

Publication provides update on the origins and causes of anxiety disorders

Anxiety disorders are not uncommon and are often 'comorbid' with other forms of mental disorders. This publication provides an update on the origins and the causes of anxiety disorders and their related symptoms.

8 Oct 2013

Study casts light on how health care providers respond to physical violence among female veterans

A new study, published in Springer's Journal of Family Violence, casts light on how health care providers respond to the emotional, sexual and physical violence that female veterans sometimes experience at the hands of their intimate partners.

8 Oct 2013

Grandmothers can lower their stress levels with biofeedback device

In a pilot study by Case Western Reserve University's Frances Payne Bolton School of Nursing, 20 grandmothers were able to lower their stress levels with a biofeedback device that tracks breathing patterns.

8 Oct 2013

PMDD may shed light on complex interactions between sex hormones and mood

Improved understanding of the role of female sex hormones on the drivers and symptoms of premenstrual dysphoric disorder (PMDD) may shed light on the complex interactions between sex hormones and mood, potentially helping to explain the increased prevalence of mood disorders in women.

8 Oct 2013

NAC amino acid may offer new treatment options for psychiatric disorders

Improved understanding of the roles of inflammation and oxidative stress in psychiatric disorders has generated new leads in the search for novel therapies. One such investigative compound currently in clinical trials is an amino acid, N-Acetyl Cysteine (NAC), which appears to reduce the core symptoms of bipolar disorder, schizophrenia, depression, autism and cravings in addictions including cocaine, cannabis abuse and cigarette smoking.

8 Oct 2013

Brain & Behavior Research Foundation to honor 7 scientists for exceptional research on mental health

The Brain & Behavior Research Foundation celebrates the transformative power of neuroscience and psychiatric research to improve the lives of those with mental illness. Seven exceptional scientists will be honored at the Annual National Awards Dinner at the Pierre Hotel in New York City on Friday, October 25, 2013.

7 Oct 2013

Depression News and Research

Latest Depression News and Research

Alkermes' ALKS 5461 drug gets FDA Fast Track status for major depressive disorder

Transcendental Meditation technique has large effect on reducing trait anxiety, shows analysis

Lundbeck, Otsuka to continue development of Lu AE58054 compound for Alzheimer's disease

TSRI scientists identify set of compounds to treat multiple sclerosis in new way

Risk of dying from invasive breast cancer lower among multivitamin/mineral users

Alkermes announces plans to advance ALKS 5461 phase 3 program for major depressive disorder

BUSM researchers develop screening tool to detect intimate partner violence in females

UCLA investigates high rates of schizophrenia in people with 22q11.2 deletion syndrome

Alkermes completes patient enrollment in phase 3 study of aripiprazole lauroxil in schizophrenia patients

Bipolar disorder ‘distinct’ from borderline personality disorder

Short sleep duration linked to suicidal ideation

Depression impairs sleep in breast cancer, but being married helps

Retirement a sticking point for antihypertensive adherence

Brain & Behavior Research Foundation to hold research symposium on mental health

Publication provides update on the origins and causes of anxiety disorders

Study casts light on how health care providers respond to physical violence among female veterans

Grandmothers can lower their stress levels with biofeedback device

PMDD may shed light on complex interactions between sex hormones and mood

NAC amino acid may offer new treatment options for psychiatric disorders

Brain & Behavior Research Foundation to honor 7 scientists for exceptional research on mental health

Innovation in neuroscience drug discovery - eBook eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Depression News and Research

Latest Depression News and Research

Innovation in neuroscience drug discovery - eBook eBook

The Proteoform Puzzle: Unlocking the Next Frontier

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Newsletters you may be interested in